Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, east Africa

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 10-15

  Ferreira, Pedro Eduardo ^a,b   Veiga, Maria Isabel ^a,b   Cavaco, Isa ^b   Martins, J Paulo ^b   Andersson, Björn ^c   Mushin, Shaliya ^d   Ali, Abullah S ^e   Bhattarai, Achuyt ^a   Ribeiro, Vera ^b   Björkman, Anders ^a   Gil, José Pedro ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Ministry of Health Zanzibar   (Tanzania)

^e NONE

Author keywords

Artemisinin based combination therapy; CYP; Malaria; MDR1; Polymorphism; Zanzibar

Indexed keywords

ANTIMALARIAL AGENT; BENFLUMETOL; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; QUININE;

AFRICA; ANTIMALARIAL ACTIVITY; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALARIA; MALE; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID; TANZANIA;

EID: 38549176303     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815e93c6     Document Type: Article

References (53)

1. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg. 2004;71:1-15.
2. Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature. 2002;415:694-701.
3. Schellenberg D, Abdulla S, Roper C. Current issues for anti-malarial drugs to control P. falciparum malaria. Curr Mol Med. 2006;6:253-260.
4. Mutabingwa TK. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Acta Trop. 2005;95:305-315.
5. Simpson JA, Aarons L, White NJ. How can we do pharmacokinetic studies in the tropics? Trans R Soc Trop Med Hyg. 2001;95:347-351.
6. Cavaco I, Stromberg-Norklit J, Kaneko A, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005;61:15-18.
7. Bindschedler M, Lefevre G, Degen P, et al. Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants. Am J Trop Med Hyg. 2002;66:293-298.
8. Grace JM, Aguilar AJ, Trotman KM, et al. Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab Dispos. 1998;26:313-317.
9. Rodriguez-Antona C, Sayi JG, Gustafsson LL, et al. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 2005;338:299-305.
10. Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006;16:637-645.
11. Li XQ, Bjorkman A, Andersson TB, et al. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003;59:429-442.
12. Simonsson US, Jansson B, Hai TN, et al. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther. 2003;74:32-43.
13. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol, 1999;48:528-535.
14. Lefevre G, Bindschedler M, Ezzet F, et al. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci. 2000;10:141-151.
15. Aarnoudse AL, van Schaik RH, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther. 2006;80:367-74.
16. Crowe A, Ilett KF, Karunajeewa HA, et al. M. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother. 2006;50:3504-3506.
17. Hayeshi R, Masimirembwa C, Mukanganyama S, et al. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci. 2006;29:70-81.
18. Burk O, Arnold KA, Nussler AK, et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005;67:1954-1965.
19. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg. 2004;98:261-269.
20. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25-61.
21. Cavaco I, Gil JP, Gil-Berglund E, et al. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med. 2003;41:1345-1350.
22. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics. 2002;12:331-334.
23. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399-415.
24. Gardner MJ, Altman DG. Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing, 1989.
25. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002;2:1-15.
26. Parikh S, Ouedraogo JB, Goldstein JA, et al. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82:197-203.
27. Chang TK, Waxman DJ. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38:51-73.
28. Ezzet F, van Vugt M, Nosten F, et al. Pharmacokinetics and pharmacodynamics of LUM (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697-704.
29. Wernsdorfer WH. Coartemether (artemether and LUM): an oral antimalarial drug. Expert Rev Anti Infect Ther. 2004;2:181-196.
30. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
31. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15:693-704.
32. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;31:525-528.
33. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-199.
34. Tanabe M, Ieiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137-1143.
35. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343-373.
36. Omari AA, Gamble C, Garner P. Artemether-LUM (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev. 2005;19:2.
37. Hutagalung R, Htoo H, Nwee P, et al. A case-control auditory evaluation of patients treated with artemether-LUM. Am J Trop Med Hyg. 2006;74:211-214.
38. Makanga M, Premji Z, Falade C, et al. Efficacy and safety of the six-dose regimen of artemether-LUM in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg. 2006;74:991-998.
39. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;11:555-572.
40. Pukrittayakamee S, Looareesuwan S, Keeratithakul D, et al. A study of the factors affecting the metabolic clearance of quinine in malaria. Eur J Clin Pharmacol. 1997;66:487-493.
41. van Agtmael MA, Gupta V, van der Graaf CA, et al. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther. 1999;66:408-414.
42. Mehlotra RK, Ziats MN, Bockarie MJ, et al. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006;62:267-275.
43. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005;15:861-873.
44. Chelule PK, Gordon M, Palanee T, et al. MDR1 and CYP3A4 polymorphisms among African, Indian, and white populations in KwaZulu-Natal, South Africa. Clin Pharmacol Ther. 2003;74:195-196.
45. Cavaco I, Reis R, Gil JP, et al. CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med. 2003;41:606-609.
46. Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 2002;54:13-21.
47. Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos. 2005;33:884-887.
48. Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 2005;225:275-282.
49. Wojnowski L, Turner PC, Pedersen B, et al. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics. 2004;14:691-700.
50. Ameyaw MM, Regateiro F, Li T, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11:217-221.
51. Allabi AC, Horsmans Y, Issaoui B, et al. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol. 2005;61:97-102.
52. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55:560-569.
53. Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos. 2001;29:1454-1459.